Reducing Akt2 in retinal pigment epithelial cells causes a compensatory increase in Akt1 and attenuates diabetic retinopathy

Haitao Liu1, Nadezda A. Stepicheva1, Sayan Ghosh1, Peng Shang1,8, Olivia Chowdhury1, Rachel A. Daley1, Meysam Yazdankhah1,9, Urvi Gupta1, Stacey L. Hose1, Mallika Valapala2, Christopher Scott Fitting1, Anastasia Strizhakova1, Yang ShanΘ3, Derrick Feenstra4, José-Alain SahelΘ1,5, Ashwath Jayagopal6, James T. Handa7, J. Samuel Zigler Jr.7, Patrice E. Fort3, Akrit SodhiΘ7 & Debasish Sinha1,7

The retinal pigment epithelium (RPE) plays an important role in the development of diabetic retinopathy (DR), a leading cause of blindness worldwide. Here we set out to explore the role of Akt2 signaling—integral to both RPE homeostasis and glucose metabolism—to DR. Using human tissue and genetically manipulated mice (including RPE-specific conditional knockout (cKO) and knock-in (KI) mice), we investigate whether Akts in the RPE influences DR in models of diabetic eye disease. We found that Akt1 and Akt2 activities were reciprocally regulated in the RPE of DR donor tissue and diabetic mice. Akt2 cKO attenuated diabetes-induced retinal abnormalities through a compensatory upregulation of phospho-Akt1 leading to an inhibition of vascular injury, inflammatory cytokine release, and infiltration of immune cells mediated by the GSK3β/NF-κB signaling pathway; overexpression of Akt2 has no effect. We propose that targeting Akt1 activity in the RPE may be a novel therapy for treating DR.

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes, and is the leading cause of blindness among working-age adults in the developed world1–4. DR can be clinically classified into two stages: non-proliferative and proliferative1. The prevailing hypothesis is that the proliferative phase is secondary to the capillary degeneration that occurs during the progression of the non-proliferative stage5–7. Therapy that halts capillary degeneration in the early stages of the disease may be beneficial in delaying the progression to proliferative DR and severe irreversible vision loss5–9.

Many retinal cell types are affected in DR, such as intense loss of inner retinal neurons9, dysfunction of Müller cells9 and astrocytes10, and activation of microglia11. The interaction between inner retinal cells and retinal vascular lesions12,13 as well as the influence of photoreceptors (inflammatory signals)14,15, retinal ganglion cells (angiogenic factors)16, astrocytes (glucose metabolism and mitochondrial function)12, and microglia (immune response)11 on retinal vascular abnormalities in diabetes have been extensively studied. These findings have greatly improved our appreciation for the multiple signaling pathways and myriad of cell types in the retina that contribute to the pathogenesis of DR.

In contrast to the role of the neurosensory retinal cells, the contribution of the retinal pigment epithelium (RPE) in early DR remains

1Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2School of Optometry, Indiana University, Bloomington, IN, USA. 3Kellogg Eye Center, University of Michigan School of Medicine, Ann Arbor, MI, USA. 4Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland. 5Institut de la Vision, INSERM, CNRS, Sorbonne Université, Paris, France. 6Opus Genetics, Durham, NC, USA. 7The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 8Present address: Doheny Eye Institute, Pasadena, CA, USA. 9Present address: Neural Stem Cell Institute, Rensselaer, NY, USA. e-mail: Debasish@pitt.edu
less clear. The RPE is a monolayer of polarized multifunctional pigmented cells that form the outer blood-retina barrier (BRB) and is crucial for maintenance of retinal function. Recent studies suggest that the RPE may also contribute to the development of DR. Loss of insulin receptor-mediated signaling in the RPE reduced both the levels of reactive oxygen species and the expression of pro-inflammatory cytokines in the retina of diabetic mice, providing evidence that the RPE could be involved in the development of DR. Indeed, treatment with the visual cycle inhibitor retinylamine (Ret-NH2), which selectively inhibits RPE65 in the RPE, prevents diabetes-induced retinal capillary degeneration. However, how the RPE affects retinal blood vessels in diabetes and how diabetes-induced changes in the RPE trigger infiltration and/or activation of immune cells in the retina remain unclear.

To narrow down the signaling pathways within the RPE that might contribute to the progression of DR, we focused on Akt signaling since it is integral to both RPE homeostasis and glucose metabolism. Akt has three isoforms, Akt1, Akt2, and Akt3 that are encoded by three separate genes. Akt1 and Akt3 are the main isoforms in the retina and their activity is affected by diabetes. Akt2 is also reported to be expressed in the retina, which suggests functional redundancy. However, it has been demonstrated that in photoreceptors, the neuroprotective role of Akt2 could not be compensated by either Akt1 or Akt3, which is in contrast to the functional overlap and the compensation observed in whole-body knockouts. Akt1 is an important regulator of cell survival and protein synthesis, and homozygous disruption results in extensive growth retardation. Because Akt3 is predominantly expressed in the brain, whole-body Akt3 knockout mice have a small brain size. Importantly, Akt2 is the isoform that has been most studied in diabetes, because it acts downstream of insulin receptor (IR) signaling. Notably, while Akt2 expression is generally lower than that of Akt1, it is expressed at high levels in insulin-responsive tissues, and plays an important role in maintaining glucose metabolism. Indeed, a family with loss of Akt2 function due to a missense mutation displays severe insulin resistance and diabetes, just as Akt2 global knockout mice display a severe type-II diabetes phenotype. However, no retina phenotype was reported in this study. Furthermore, Akt2 is activated in the retinas of mice following sorbitol-induced hyperosmotic stress, which mimics aspects of diabetic hyperglycemia. However, a contribution for Akt2 expression in the RPE to the development of DR has not been demonstrated. Here, we show Akt2 and Akt1 activities are reciprocally regulated in the RPE of DR donor tissue and diabetic mice. RPE-specific knockout of Akt2 attenuates diabetes-induced retinal molecular alterations and vascular lesions. Further, overexpressing Akt1 in RPE inhibits diabetes-induced retinal abnormalities and loss of Akt1 function in retina/RPE accelerates retinal vascular damage in diabetic mice. Thus, this work provides a foundation for targeting Akt1 as a promising therapeutic approach for the treatment of DR.

Results
The diabetes-induced impairment of retinal function is rescued in RPE-specific Akt2 cKO mice
To address the role of Akt2 signaling in DR, RPE-specific Akt2 cKO mice were generated (Supplementary Fig. 1a). The changes in the Akt2 level were validated by western blotting, confirming that both phospho- and total-Akt2 levels were decreased in the RPE from Akt2 cKO mice compared to Akt2fl/fl controls (Supplementary Fig. 1b). Akt2 is not completely knocked out in Akt2 cKO mice due to the mosaic expression of the Best gene (the Cre gene utilizes the Best1 promotor) in the RPE, resulting in heterogenous loss of the floxed allele. Accordingly, immunofluorescence studies for Cre performed on Akt2 cKO RPE flatmounts demonstrated the mosaic expression of Cre protein in RPE cells (Supplementary Fig. 1c). Diabetes was induced by intraocular (IP) injection of streptozotocin (STZ); the successful induction of diabetes was confirmed by an increase in non-fasting blood glucose (>275 mg/dL) levels and the inability of the mice to gain body weight (Supplementary Table 1). In addition, hemoglobin Alc (HbAlc) was measured to assess the severity of hyperglycemia over time (HbAlc is typically 3.0% in nondiabetic mice and between 7.5 and 8.6% in diabetic mice; Supplementary Table 1). The severity of diabetes in the Akt2 cKO mice was similar to Akt2fl/fl controls. Blood glucose, HbAlc, and body weights were similar among the nondiabetic groups. It has previously been reported that degenerative changes in the retina are early events in the development of DR. Therefore, we tested retinal function by electroretinography (ERG), which allows for effective assessment of photoreceptor activity (a-wave), Müller and bipolar cell activity (b-wave), and RPE function (c-wave). With prolonged diabetes (4 months after induction) the amplitudes of dark-adapted scotopic a- and b-waves (Fig. 1a–c), as well as the light-adapted photopic b-wave were reduced in Akt2fl/fl mice compared to nondiabetic controls at high flash levels (Fig. 1d, e). Importantly, the c-wave amplitude in diabetic Akt2fl/fl mice compared to nondiabetic animals was also decreased (Fig. 1f, g), indicating that the retinal and RPE cells are severely affected. Notably, RPE-specific Akt2 cKO reversed the diabetes-induced impairment of the retina and RPE function. We also found that scotopic and photopic ERGs are similar in Akt2 cKO and Akt2fl/fl diabetic mice (Fig. 1a–c) at low flash levels, suggesting that cones may be primarily affected. We next investigated cone and rod morphology under normal and diabetic conditions (Supplementary Fig. 2a) and observed that cones (stained with opsin antibody; red) are disorganized in Akt2fl/fl diabetic mice. However, Akt2 cKO normalized cone morphology in diabetic animals, as evident from the parallel orientation and highly organized structure of the cone photoreceptor outer and inner segments, consistent with a previous publication. Interestingly, rod cell (stained with rhodopsin; green) morphology was similar between Akt2fl/fl and Akt2 cKO nondiabetic and diabetic mouse retinas (at a 2 month duration of diabetes). Since cones constitute ~3% of the photoreceptor population in mice, gradual loss of both rods and cones would result in a greater percentage loss of cones than rods at early time points and hence loss of cone function would be identifiable prior to rod dysfunction, as reported here. Collectively, these results suggest that the RPE is not just passively affected by diabetes but also directly contributes to changes in the neural retina, and that Akt2 signaling in the RPE might play a central role. This is consistent with prior reports implicating the RPE in the development of diabetic retinopathy. We therefore set out to further delineate the molecular mechanism whereby AK2 signaling in the RPE helps maintain retinal vascular homeostasis in diabetes.

Loss of Akt2 function in the RPE prevents increased levels of inflammatory proteins, leukostasis, and production of ROS in the diabetic retina
Retinal inflammation, leukostasis and oxidative stress have all been implicated in early DR pathogenesis. We previously reported that Akt2 regulates inflammation in the RPE cells. To determine if Akt2 in RPE cells influences inflammatory proteins, leukostasis and the production of ROS in the diabetic retina, RPE-specific Akt2 cKO mice, along with Akt2fl/fl controls, were analyzed after 2 months of diabetes. The diabetes-induced increases in the level of inflammatory proteins iNOS and ICAM-1, and in the ratio of pkBα/pkB in the neural retina were inhibited in Akt2 cKO diabetic mice compared to Akt2fl/fl diabetic controls (Fig. 2a–d). This inhibition suggests that decreasing Akt2 specifically in the RPE protects against diabetes-induced inflammatory changes in the neural retina. ICAM-1 is known to mediate the attachment of leukocytes to retinal endothelial cells, thus promoting leukostasis, an important pathogenic event in the development of DR. Interestingly, we observed fewer leukocytes attached to the retinal
vasculature of RPE-specific Akt2 cKO diabetic mice compared to control diabetic mice (Fig. 2e, f). Taken together, these data suggest that Akt2 in the RPE promotes the diabetes-induced increase of neural retinal inflammation that mediates leukostasis within the retinal vasculature through ICAM-1.

Diabetes-induced increase of retinal superoxide and leukostasis were reported to be inhibited in NOS-deficient mice, suggesting that ROS production is linked to inflammation5. Moreover, antioxidant therapies such as vitamin C and E, or overexpression of superoxide dismutase 1 (SOD1) in diabetic mice inhibit capillary degeneration, indicating that oxidative stress is a critical pathogenic factor in microvascular injury in the diabetic retina6,7. Thus, we examined retinal ROS production in these mouse models. ROS generated in the retina were assessed using freshly isolated retinas incubated with dichlorodihydrofluorescein diacetate (DCF, which reacts with superoxide), and by staining cryosections of diabetic rat retinas with DHE and DCF fluorescence intensity was assessed in RPE-specific Akt2 cKO mice compared to nondiabetic controls. However, Akt2 cKO diabetic mice (Fig. 3f). We also observed that subsets within the infiltrating leukocyte population, which reacts with ROS). Superoxide production was markedly attenuated in RPE-specific Akt2 cKO diabetic mice (Fig. 2g). DHE and DCF staining enabled us to visualize the localization of ROS within the retina. DHE turns red in the presence of superoxide and intercalates with DNA thereby staining nuclei. We found that diabetes-induced superoxide is mainly generated in the inner and outer nuclear layers (INL/ONL) of the retina (Fig. 2h). The red fluorescence intensity was lower in the RPE-specific Akt2 cKO diabetic mice compared to control diabetic controls (Fig. 2i). DCF turns green when reacting with ROS (Fig. 2); this staining revealed an increase in ROS levels in the photoreceptor inner/outer segments of diabetic Akt2 cKO controls, but not in diabetic Akt2 cKO mice (Fig. 2k). Collectively, these data suggest that retinal production of ROS, one of the important contributors to DR, may be caused by activation of iNOS by Akt2 in RPE in the diabetic retina.

Deleting Akt2 in the RPE inhibits diabetes-induced infiltration of leukocytes in the retina/RPE

Previous studies showed that recruitment of inflammatory cells plays an important role in diabetic eye disease5,8. Indeed, leukocytes isolated from diabetic patients and mice have been shown to induce the death of retinal endothelial cells9,10. Moreover, retinal capillary degeneration in diabetic animals is inhibited if ICAM-1 is absent or Neutrophil Inhibitory Factor (NIF) is overexpressed11,12. Further studies also showed that neutrophil elastase secreted by neutrophils contributes to retinal vascular leakage in DR9. To determine if the protective effects observed in Akt2 cKO mice could be due to reduced infiltration of leukocytes into the retina, we performed a quantitative analysis of the leukocytes in retinas from these mice. To this end, we isolated the retina and RPE from diabetic (2 months of diabetes) and age-matched nondiabetic mice. Each retina/RPE preparation was digested to make a cell suspension, followed by immunostaining for flow cytometry to determine the extent of infiltration of various immune cells. The gating strategy is shown in Fig. 3a–e. As expected, diabetes increased the infiltration of leukocytes (CD11b+CD45+Mφ) in the retina of Akt2 cKO mice compared to control diabetic mice. However, Akt2 cKO diabetic mice had noticeably fewer infiltrating leukocytes in the retina/RPE compared to Akt2 cKO diabetic mice (Fig. 3f). We also observed that subsets within the infiltrating leukocyte population,
specifically neutrophils (CD11b'CD45hiLy6ChighLy6G') and monocytes (CD11b'CD45hiLy6CnegCCR2'), were increased in the Akt2cKO diabetic mice. These diabetes-induced increases were not observed in the Akt2cKO diabetic mice (Fig. 3g, h).

Knockout of Akt2 in the RPE prevents diabetes-induced retinal capillary degeneration and vascular leakage
Collectively, these data demonstrate that knockout of Akt2 in the RPE reduces inflammatory cell infiltration, leukostasis, and degeneration of
the retina. To determine if these changes were sufficient to protect against retinal vascular lesions in DR, we examined the retinas of Akt2fl/fl and Akt2 cKO mice that had been diabetic for several months and manifested retinal vascular changes. The duration of diabetes was prolonged to 8 months because retinal capillary degeneration and vascular leakage becomes prominent by this stage. We observed an increase in acellular capillaries (Fig. 4a, arrows) and a decrease in capillary pericytes (Fig. 4a, arrowheads), both hallmarks of early-stage DR, in the retinas of Akt2fl/fl diabetic mice compared to nondiabetic controls. However, these diabetes-induced defects were strikingly reduced in the retinas of Akt2fl/fl diabetic mice compared to nondiabetic controls. Interestingly, Akt2 cKO mice demonstrated noticeable decline in the diabetes-induced increase in retinal neutrophil and monocyte infiltration. In (F–H), data are shown as Mean ± SD. N = 4 animals per group. **p < 0.01 and ***p < 0.001 denotes changes versus Akt2fl/fl nondiabetic group. *p < 0.05, and **p < 0.01, shows changes versus Akt2fl/fl diabetic mice. Statistical test used in (F–H) is One-way ANOVA followed by a Tukey’s post hoc test. Exact p values are: f p = 0.0026 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.025 (Akt2 cKO D vs. Akt2fl/fl D). g p = 0.0001 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.0031 (Akt2 cKO D vs. Akt2fl/fl D). h p = 0.0001 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.025 (Akt2 cKO D vs. Akt2fl/fl D).

Generation and characterization of a DR phenotype in Akt2KI (knockin) mice with RPE-specific overexpression of Akt2
Since loss of Akt2 function in the RPE protected against diabetes-induced retinopathy, we examined whether increased Akt2 would have the reverse effect by generating RPE-specific Akt2KI mice and inducing diabetes with STZ (Supplementary Fig. 3a). Diabetes was confirmed by a significant increase in the levels of non-fasting blood glucose (~275 mg/dL)42, and reduced increase in body weight (Supplementary Table 1)42. The severity of diabetes in the KI group and WT controls was not different. In nondiabetic groups, the blood glucose, HbA1c, and body weights were similar (Supplementary Table 1). We confirmed by western blotting that levels of both phospho- and total-Akt2 were higher in the RPE from Akt2 cKO mice compared to WT control mice (Supplementary Fig. 3b). Only a subset (~60–70%) of RPE cells express the Best1 gene in the wild type and Akt2 KI mice (Supplementary Fig. 3c).

Surprisingly, we observed no significant change in the c-wave (RPE function) between Akt2 KI and WT diabetic mice (Fig. 5a–g), suggesting that RPE-specific overexpression of Akt2 had no effect on the diabetes-induced impairment of retinal function. In addition, the expression of inflammatory markers and leukostasis (Fig. 6a–f) and the levels of ROS production (Fig. 6g–k), were not different between KI and WT diabetic mice. Accordingly, the number of retinal acellular capillaries and capillary pericytes, the levels of retinal vascular leakage (Fig. 7a–e), as well as the infiltration of leukocytes (Supplementary Fig. 4) into the retina were similar in Akt2 KI and WT diabetic mice.

the retina. To determine if these changes were sufficient to protect against retinal vascular lesions in DR, we examined the retinas of Akt2fl/fl and Akt2 cKO mice that had been diabetic for several months and manifested retinal vascular changes. The duration of diabetes was prolonged to 8 months because retinal capillary degeneration and vascular leakage becomes prominent by this stage. We observed an increase in acellular capillaries (Fig. 4a, arrows) and a decrease in capillary pericytes (Fig. 4a, arrowheads), both hallmarks of early-stage DR, in the retinas of Akt2fl/fl diabetic mice compared to nondiabetic controls. However, these diabetes-induced defects were strikingly reduced in the retinas of Akt2fl/fl diabetic mice compared to nondiabetic controls. Interestingly, Akt2 cKO mice demonstrated noticeable decline in the diabetes-induced increase in retinal neutrophil and monocyte infiltration. In (F–H), data are shown as Mean ± SD. N = 4 animals per group. **p < 0.01 and ***p < 0.001 denotes changes versus Akt2fl/fl nondiabetic group. *p < 0.05, and **p < 0.01, shows changes versus Akt2fl/fl diabetic mice. Statistical test used in (F–H) is One-way ANOVA followed by a Tukey’s post hoc test. Exact p values are: f p = 0.0026 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.025 (Akt2 cKO D vs. Akt2fl/fl D). g p = 0.0001 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.0031 (Akt2 cKO D vs. Akt2fl/fl D). h p = 0.0001 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.025 (Akt2 cKO D vs. Akt2fl/fl D).

Generation and characterization of a DR phenotype in Akt2KI (knockin) mice with RPE-specific overexpression of Akt2
Since loss of Akt2 function in the RPE protected against diabetes-induced retinopathy, we examined whether increased Akt2 would have the reverse effect by generating RPE-specific Akt2KI mice and inducing diabetes with STZ (Supplementary Fig. 3a). Diabetes was confirmed by a significant increase in the levels of non-fasting blood glucose (~275 mg/dL)42, and reduced increase in body weight (Supplementary Table 1)42. The severity of diabetes in the KI group and WT controls was not different. In nondiabetic groups, the blood glucose, HbA1c, and body weights were similar (Supplementary Table 1). We confirmed by western blotting that levels of both phospho- and total-Akt2 were higher in the RPE from Akt2 cKO mice compared to WT control mice (Supplementary Fig. 3b). Only a subset (~60–70%) of RPE cells express the Best1 gene in the wild type and Akt2 KI mice (Supplementary Fig. 3c).

Surprisingly, we observed no significant change in the c-wave (RPE function) between Akt2 KI and WT diabetic mice (Fig. 5a–g), suggesting that RPE-specific overexpression of Akt2 had no effect on the diabetes-induced impairment of retinal function. In addition, the expression of inflammatory markers and leukostasis (Fig. 6a–f) and the levels of ROS production (Fig. 6g–k), were not different between KI and WT diabetic mice. Accordingly, the number of retinal acellular capillaries and capillary pericytes, the levels of retinal vascular leakage (Fig. 7a–e), as well as the infiltration of leukocytes (Supplementary Fig. 4) into the retina were similar in Akt2 KI and WT diabetic mice.
that the induction of diabetes increased the level of phospho-Akt2 expression of pro-inflammatory response. To test this hypothesis, we looked at the level of Akt2 cKO inhibited such diabetes-induced changes in the RPE, as supported by the comparison of Akt2 cKO diabetic mice with Akt2fl/fl diabetic controls (Fig. 8g, h).

It has been reported that GSK3β signaling is involved in the regulation of inflammation and leukocyte infiltration. Thus, it is possible that Akt2 knockout in the RPE has a protective effect against diabetes through upregulated Akt1, further inhibiting a GSK3β/NF-κB-regulated inflammatory response. To test this hypothesis, we looked at the level of downstream inflammatory proteins, ICAM-1 and INOS in the RPE after 2 months of diabetes. Similar to the retina (Fig. 2b, c), the diabetes-induced increase in ICAM-1 and INOS protein was inhibited in the RPE from Akt2 cKO diabetic mice compared to WT diabetic mice (D). Statistical test used in (b, c, e) is One-way ANOVA followed by a Tukey’s post hoc test. Exact p values are: b. p < 0.0001 (Akt2fl/fl vs. Akt2fl/fl N), p = 0.0096 (Akt2 cKO D vs. Akt2fl/fl D). c. p = 0.0008 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.0187 (Akt2 cKO D vs. Akt2fl/fl D). e. OPL, p = 0.0046 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.0388 (Akt2 cKO D vs. Akt2fl/fl D); INL, p = 0.0002 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.0087 (Akt2 cKO D vs. Akt2fl/fl D). p < 0.0001 (Akt2fl/fl D vs. Akt2fl/fl N), p = 0.0009 (Akt2 cKO D vs. Akt2fl/fl D), cKO conditional knockout, INL inner plexiform layer, INL inner nuclear layer, OPL outer plexiform layer.

Akt2 cKO promotes upregulation of Akt1 and prevents the diabetes-induced increased protein levels of ICAM-1 and INOS in the RPE by mediating the GSK3β/NF-κB signaling pathway.

To investigate further how the lack of Akt2 in the RPE protects the retina from diabetes-induced abnormalities, we focused on Akt1 and its downstream targets. We first analyzed the activity of Akt2 by evaluating the ratio of phospho-Akt2/total Akt2. We found that specific activity of Akt2 is increased while that of Akt1 is decreased in Akt2fl/fl diabetic mice compared to Akt2fl/fl nondiabetic controls. We also found that the induction of diabetes increased the level of phospho-Akt2 (active Akt2), but not total-Akt2 in Akt2fl/fl diabetic mice compared to Akt2fl/fl nondiabetic controls (Fig. 8a–c). As expected, Akt2 cKO inhibited the diabetes-induced increase of phospho-Akt2 in the RPE (Fig. 8b). In contrast, the level of phospho-Akt1 was lower in the RPE of Akt2fl/fl diabetic mice, while total Akt1 remained the same. Interestingly, both phospho- and total Akt1 were higher in Akt2 cKO diabetic mice compared to Akt2fl/fl nondiabetic mice (Fig. 8a, d, e). However, in Akt2 cKO nondiabetic mice only total Akt1, and not the phospho-Akt1, was upregulated, compared to Akt2fl/fl nondiabetic controls (Fig. 8a, d, e). These results suggest that diabetes is regulating phospho-Akt1 and Akt2 in a reciprocal manner.

To examine whether the diabetes-induced increase in the expression of pro-inflammatory proteins in the RPE is influenced by Akt1 downregulation, we evaluated the level of Akt1 downstream targets. Induction of diabetes decreased the ratio of phospho-GSK3β/GSK3β, and increased the proportion of phospho-NF-κB p65/NF-κB p65 in the RPE of Akt2fl/fl diabetic mice compared to Akt2fl/fl nondiabetic controls (Fig. 8i). Akt2 cKO inhibited such diabetes-induced changes in the RPE, as supported by the comparison of Akt2 cKO diabetic mice with Akt2fl/fl diabetic controls (Fig. 8g, h).

Both phospho- and total-Akt2 were increased in Akt2 fl/fl mice (both nondiabetic and diabetic) compared to WT nondiabetic controls. Similar to Akt2fl/fl RPE, diabetes increased the level of phospho-Akt2, but not total Akt2, in WT mice (Supplementary Fig. 5a–c). Diabetes also reduced phospho-Akt1, but not total Akt1, in both WT diabetic and Akt2 fl/fl diabetic mice compared to corresponding nondiabetic controls, suggesting that Akt2 fl/fl had no effect on the
diabetes-induced downregulation of phospho-Akt1 in the RPE (Supplementary Fig. 5d, e). Moreover, Akt2 KI neither altered the phosphorylation of GSK3β or NF-κB (Supplementary Fig. 5f, g) nor affected the level of downstream inflammatory proteins in the RPE of Akt2 KI diabetic mice (Supplementary Fig. 5h, i).

The inverse correlation between Akt2 and Akt1 was also confirmed by in vitro studies using Akt2 siRNA. The protein levels of phospho- and total-AKT2 and AKT1 were assayed by western blotting in human fetal RPE (fRPE) cells cultured in presence of high glucose (25 mM) medium with or without Akt2 siRNA (Supplementary Fig. 6a, b). Downregulation of AKT2 in fRPE cells markedly increased the ratio of phospho-AKT1/AKT1 without causing any significant change in the upstream regulators of AKT such as the ratios of phospho-PDK1/PDK1 and phospho-PI3K/PI3K (Supplementary Fig. 6b).

Representative scotopic ERG a- and b-waveforms, showing response to a 0 log10 cd·s/m² stimulus luminance after overnight dark adaptation. Scotopic (b) a-wave and (c) b-wave amplitudes were decreased in both WT and Akt2 KI diabetic mice compared to appropriate nondiabetic controls. Akt2 overexpression in the RPE (Akt2 KI) did not exhibit any protective effect on diabetic-induced ERG abnormalities. d Representative photopic ERG b-waveforms response to a 1 log10 cd·s/m² stimulus luminance after light adaptation. e RPE-specific Akt2 KI had no protective effect on the diabetes-induced detrimental changes in the photopic b-wave. f Representative ERG c-waveforms. g c-wave amplitude is decreased in WT and Akt2 KI diabetic mice compared to appropriate nondiabetic controls. There was no significant change in the c-wave between diabetic WT and Akt2 KI groups.

Diabetes-induced upregulation of inflammatory cytokines in the retina and RPE was essentially absent in the Akt2 cKO mice (Fig. 9b). These results were corroborated in RPE explant cultures (Fig. 9c). We also observed that the inhibition of inflammatory cytokines in the RPE explants from Akt2 cKO diabetic mice was largely abolished by adding an Akt1 inhibitor to the culture medium for 48 h (Fig. 9c). These data further support the hypothesis that knockout of Akt2 in the RPE inhibits diabetes-induced inflammatory responses through the upregulation of Akt1.

To further interrogate the relationship between Akt2 and Akt1 in the diabetic RPE, Akt isoforms and their downstream target proteins were analyzed by western blots on extracts from cultured RPE explants with and without Akt2 cKO (Supplementary Fig. 6d). Akt2 knockdown in the RPE increases the level of phospho-Akt2 and the proportion of phospho-GSK3β (Supplementary Fig. 7a). These data suggest that decreasing Akt2 in the RPE inhibits diabetes-induced retinal abnormalities in mice, through the upregulation of Akt1, and, in turn inhibition of the GSK3β/NF-κB-regulated inflammatory response.
Fig. 6 | RPE-specific Akt2 KI does not influence the diabetes-induced increase in pro-inflammatory protein level, leukostasis, or production of reactive oxygen species in mice after 2 months of diabetes. a Representative immunoblots and densitometry graphs showing that the diabetes-induced increase in the levels of pro-inflammatory markers (b) ICAM-1, (c) iNOS, and (d) the ratio of pIκB/IκB were not significantly decreased in Akt2 KI diabetic mice compared to WT diabetic mice. This result is in contrast to that found with Akt2 cKO mice (e). Representative images and (f) quantification of retinal leukostasis from each group. Arrows indicate leukocytes adherent to the retinal blood vessels. Diabetes increased the number of adherent leukocytes in the retina of both WT and RPE-specific Akt2 KI mice; Scale bar: 100 µm.

Retinal superoxide was measured using the lucigenin method. Diabetes increased retinal superoxide production in both diabetic WT and Akt2 KI mice. (h) Representative images and (i) quantification of dihydroethidium (DHE)-stained (red) ROS. Scale bar: 100 µm. Red fluorescence intensity (DHE stain) was quantified at the INL and ONL together as they represent the majority of staining in the retina. Diabetes increased the production of retinal ROS in both WT and Akt2 KI mice. j Representative images and (k) quantification of dichlorofluorescein (DCF) stained ROS. The DCF stain is localized primarily in the inner and outer segments of photoreceptors. The blue (nuclear) stain is DAPI. Diabetes induced an increase of ROS in the retina of both diabetic WT and Akt2 KI mice compared to appropriate nondiabetic controls. Scale bars: 100 µm. In (b–d, f, i, k), n = 6 mice for each group, data are represented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 represent changes versus WT N. †p < 0.05, ††p < 0.01, †††p < 0.001, and ††††p < 0.0001 denote changes versus Akt2 KI N. Statistical test used in this study is One-way ANOVA followed by a Tukey’s post hoc test. Exact p values are: b p = 0.004 (WT D vs. WT N), p < 0.0001 (Akt2 KI D vs. WT N, Akt2 KI D vs. Akt2 KI N). c p = 0.0019 (WT D vs. WT N), p < 0.0001 (Akt2 KI D vs. WT N, Akt2 KI D vs. Akt2 KI N). d p = 0.0231 (WT D vs. WT N), p = 0.0004 (Akt2 KI D vs. WT N) f p = 0.0033 (WT D vs. WT N), f p = 0.0001 (Akt2 KI D vs. WT N, Akt2 KI D vs. Akt2 KI N). e p = 0.0001 (Akt2 KI D vs. WT N), e p = 0.0002 (Akt2 KI D vs. WT N). f p = 0.0001 (Akt2 KI D vs. WT N), p = 0.0005 (Akt2 KI D vs. WT N, Akt2 KI D vs. Akt2 KI N). h p = 0.0012 (Akt2 KI D vs. WT N), p = 0.012 (Akt2 KI D vs. WT N). i p < 0.0001 (Akt2 KI D vs. WT N), p = 0.0002 (Akt2 KI D vs. WT N), p = 0.0015 (Akt2 KI D vs. WT N, Akt2 KI D vs. WT N), p < 0.0001 (Akt2 KI D vs. WT N, Akt2 KI D vs. WT N). j p = 0.0003 (Akt2 KI D vs. WT N), p = 0.0001 (Akt2 KI D vs. WT N, Akt2 KI D vs. WT N). k p < 0.0001 (WT D vs. WT N), p = 0.0011 (Akt2 KI D vs. WT N), p = 0.017 (Akt2 KI D vs. WT N). WT wild type, N nondiabetic, D diabetic, KI knock-in, GCL ganglion cell layer, INL inner nuclear layer, ONL outer nuclear layer, RIS/ROS rod inner/outer segment. Source Data is provided in the Source Data file.
Increased Akt1 signaling in the RPE prevents increased levels of inflammatory proteins and superoxide production in the diabetic retina; loss of Akt1 activity accelerates diabetes-induced retina vascular damage

These results suggest that the protective effect observed in RPE-specific Akt2 cKO mice is due to the upregulation of Akt1. We therefore speculated that increasing Akt1 activity specifically in the RPE may serve as an effective intervention to treat DR. To test this, we over-expressed Akt1 in RPE by subretinal injection (SRI) of AAV2-hRPE-GFP-P2A-mAkt1 (once per month) in WT diabetic mice when diabetes induction was confirmed in these mice 7 days post STZ injection. After 2 months of treatment, we found decreased expression of the inflammatory proteins, INOS and ICAM-1, as well as the ratio of pIkB/IkB in the retina of diabetic mice overexpressing Akt1 in their RPE, compared to diabetic mice treated with the control vector, AAV2-hRPE-EGFP (Supplementary Fig. 7a–f). Retinal superoxide production was also markedly reduced in these RPE-specific Akt1 overexpressing diabetic mice (Supplementary Fig. 7g). These data suggest that increasing Akt1 function specifically in the RPE protects against diabetes-induced inflammatory changes and oxidative stress in the retina.

To further confirm that decreased Akt1 activity in RPE is detrimental in DR, we administered an Akt1 inhibitor to diabetic mice by intravitreal injection (ITVI) or SRI. After 4 months of treatment (once per month), when mice were diabetic for 4 months (6 months of age), we evaluated retinal vascular damage, and found that diabetes had not produced significant retinal capillary degeneration or pericyte loss. However, in the presence of the Akt1 inhibitor in the retina and RPE, such vascular changes were exacerbated as evident from increased number of acellular capillaries and loss of pericytes in the retina (Supplementary Fig. 7h–j). This suggests that modulation of Akt1 in the retina/RPE may play an important role in diabetes-induced early retinal molecular alterations such as inflammation and oxidative stress and pathological changes such as capillary degeneration and pericyte loss.

Diabetes-induced ROS regulates Akt2, but not Akt1 in the RPE through PI3K/PDK1 signaling

To explore how diabetes triggers reciprocal regulation of Akt1 and Akt2 in RPE, we investigated the upstream regulators of Akt and found that diabetes increased the ratio of p-PDK1/PDK1 and the ratio of p-PI3K/PI3K in RPE of 2 months diabetic mice compared to age-matched nondiabetic wild type controls. This correlated with the
obtained from diabetic and nondiabetic animals, we isolated and cultured RPE explants from diabetic and nondiabetic mice (Supplementary Fig. 8d). These results suggest that the hyperglycemia-induced increase in Akt2 phosphorylation in the RPE is possibly regulated by ROS through the PI3K/PDK1 signaling, while the decreased Akt1 activity is not regulated by ROS and is independent of PI3K/PDK1 signaling.

High glucose increased Akt2 phosphorylation and diminished Akt1 activity in the RPE by PI3K/PDK1 dependent and independent pathways

Consistent with our findings in the RPE of diabetic mice, reciprocal regulation of AKT1 and AKT2 phosphorylation in the RPE was observed in human diabetic retinopathy donor cadaver samples, compared to nondiabetic controls (Supplementary Fig. 9a, b). Basic characteristics of human RPE cadaver tissue donors are provided in Supplementary Table 2. To confirm these findings, human RPE cells were cultured in low (5 mM) and high (25 mM) glucose medium for 1, 2 and 4 days. We found that after 1 day of high glucose exposure there was a substantial elevation of p-Akt2/Akt2 (Supplementary Fig. 8a–c). We reported here that diabetes increases retinal production of ROS, which in turn, have been reported to activate Akt in RPE cells81. To confirm whether elevated p-Akt2/Akt2 ratio in the RPE is caused by ROS via the PI3K/PDK1 signaling pathway in diabetic animals, we isolated and cultured RPE explants from wild type diabetic and nondiabetic mice, with or without an antioxidant (N-acetylcysteine; NAC) or PI3K inhibitor (LY294002) for 24 h. Both NAC and LY294002 treatments lowered the phospho-Akt2/Akt2, phospho-PDK1/PDK1 and phospho-PI3K/PI3K ratios in the RPE explant lysates from diabetic mice in comparison to the untreated RPE-explants from diabetic mice. However, there was no significant change in phospho-Akt1/Akt1 after NAC and LY294002 treatments in comparison to control untreated RPE explants from diabetic mice (Supplementary Fig. 8d–h). These results suggest that the hyperglycemia-induced increase in Akt2 phosphorylation in the
increase in Akt1 activity, as evident from the elevated ratio of p-AKT1/ AKT1, compared to low glucose conditions. However, AKT1 activity declined after 2 days in high glucose culture conditions, and returned to near control levels by 4 days (Supplementary Fig. 9c, d). On the other hand, the high glucose treatment induced a sustained increase in AKT2 activity (ratio of phospho-AKT2/AKT2) as seen after 1, 2 and 4 days of incubation (Supplementary Fig. 9e). The change in AKT2 activity is coincident with increased phospho-PDK1/PDK1 and phospho-PI3K/PI3K ratios after cells were grown in a high glucose medium (25 mM D-glucose) for 2 and 4 days, suggesting that high glucose-induced elevation of AKT2 activity may be modulated via the PI3K/PDK1 signaling pathway, similar to our observations in the RPE cells of WT diabetic mice. These data confirm that AKT1 and AKT2 activities function inversely in the human RPE and particularly in DR donor cadaver RPE, and that high glucose may serve to increase AKT2 activity through PI3K/PDK1 signaling. We also found high glucose-induced alterations in phospho- and total AKT2, PDK1, and PI3K in human fRPE cells maintain their significance when compared to the osmotic controls (source data). Thus, the effects observed in this study are high glucose specific. The fPRE cells cultured in high glucose condition did not show decreased AKT1 activity as seen in the RPE of human DR donors. This suggest that the decreased AKT1 activity in RPE from human diabetic DR donors, similar to diabetic mice may be regulated by factors other than high glucose, and seemingly independent of PI3K/PDK1 signaling.

Previous studies have reported increased cellular (specifically mitochondrial) ceramide in RPE cells derived from diabetic patients. An important ceramide metabolism dysregulation in the diabetic retina is the shift in the spectrum of sphingolipid forms from protective very long chain (VLC) ceramides (C≥26) to pro-inflammatory and proapoptotic short-chain (SC) ceramides (C≤24) which are mainly produced from sphingomyelins by acid sphingomyelinase (ASM). Of interest, ceramide has been shown to inhibit Akt1 in RPE independent of the PI3K signaling pathway. To determine whether ceramide plays a role in the reduction in Akt1 activity, human fRPE cells were treated with C6-ceramide (H6524 Sigma-Aldrich) at concentrations of 2, 10,
and 50 μM respectively under high glucose conditions (25 mM) for 4 days. We found that ceramide reduced Akt1 activity as indicated by reduced p-Akt1/Akt1 ratio at all three concentrations tested (Supplementary Fig. 9h, i). Akt2 activity was also decreased upon ceramide treatment but only at the higher concentrations, compared to cells without ceramide treatment (Supplementary Fig. 9j). There were no significant differences in the ratios of phosphorylated PDK1/PDK1 and phospho-P38/P38 between ceramide-treated and untreated RPE cells. These data suggest that the decreased Akt1 activity in the RPE observed in diabetes may be caused by ceramide, independent of PI3K/PDK1 signaling. To confirm the effect of ceramide in inhibiting AKT1 activity in RPE under high glucose conditions, we incubated human RPE cells in high glucose medium with or without ASM inhibitor (desipramine; 2 μM). Our results showed elevated ASM mRNA levels in human RPE cells cultured in 25 mM D-glucose medium for 4 days (Supplementary Fig. 9m), which is consistent with previous findings showing highly upregulated ASM expression in the diabetic retina. We further found that high glucose significantly increased ceramide accumulation in the RPE cells, which was diminished by ASM inhibitor (Supplementary Fig. 9n, o). ASM-mediated decrease in endogenous ceramide was also found to be associated with increased phospho-AKT1/AKT1 ratio under high glucose conditions after 4 days (Supplementary Fig. 9g). However, the ratio of phospho-AKT2/AKT2 (Supplementary Fig. 9j), phospho-PDK1/PDK1 (Supplementary Fig. 9s) and phospho-P38/P38 (Supplementary Fig. 9r) remained higher in high glucose conditions without showing any significant difference between ASM inhibitor treated or untreated groups. We postulate that reducing ceramide by ASM inhibitor does affect AKT1 activity, at least under the specific concentration (desipramine, 2 μM) used in this study. Together with the C6-ceramide treatment study, these data suggest that the decreased AKT1 activity in the RPE observed in both diabetic mice and DR patients may be caused by increased short-chain ceramide which is possibly dependent on ASM activity, but independent of PI3K/PDK1 signaling.

**Discussion**

DR is a multifactorial disease with limited therapeutic options for patients. Few treatments that exist are aimed at preventing the progression of advanced-stage disease. As a consequence, DR remains a tremendous burden on the quality of life of the diabetic population. Identifying new pathways that contribute to disease progression, particularly in early DR, is therefore crucial for improving vision in diabetic patients in the future.

For patients with hyperglycemia, the most important risk factor in the development of DR. Nonetheless, strict control of glucose levels does not prevent disease progression in all patients. Many patients have sustained disease progression even after glucose normalization, perhaps due to metabolic memory. Anti-VEGF and laser photo-coagulation treatments have been used as an essential clinical treatment for DR patients. However, both can be associated with either unintended side effects and/or inadequate response in a majority of patients. Other contributors to DR pathogenesis include inflammation and oxidative stress. Anti-inflammatory therapies such as high-dose aspirin treatment and germline deletion of INOS inhibit retinal capillary degeneration in diabetic animals. Likewise, antioxidant therapies such as vitamin C or vitamin E treatment and overexpression of superoxide dismutase have been shown to inhibit capillary degeneration in DR animal models. While these therapies are being currently explored for the treatment of DR, to date no comprehensive solution to prevent/treat early DR exists. Thus, finding novel therapeutic approaches remains critically important.

Nature Communications | (2022) 13:6045
The three Akt isoforms, Akt1, Akt2, Akt3 are functionally distinct. Amongst these, Akt2 has been shown to play a role in diabetes\(^3\). In particular, it has been reported that Akt2 whole-body knockout mice display a severe type-II diabetes phenotype and that human patients with mutations in Akt2 show severe insulin resistance and develop diabetes\(^3\). In the retina, Akt2 was reported to be activated under sorbitol-induced hyperosmotic stress conditions, implicating Akt2 in retinal disease\(^3\). Conversely, mice lacking Akt2 showed severe diabetic retinopathy, since elevated sorbitol in diabetic retinas is known to potentiate the pathogenesis of DR\(^4\). We report here that in RPE cells from both DR eyes and diabetic mice, that Akt2 activity is increased and that this increase is driven by ROS through PI3K/PDK1 signaling. Knocking out Akt2 specifically in the RPE inhibited the diabetes-induced increases in the level of retinal inflammatory proteins, production of ROS, vascular leakage and retinal capillary degeneration. However, overexpression of Akt2 did not have the reverse effect, suggesting an indirect mechanism whereby loss of Akt2 expression in the RPE influences DR progression.

Interestingly, the level of phospho-Akt1 was found to be decreased in the retinas of STZ-induced diabetic mice, supporting the involvement of Akt1 signaling in DR pathogenesis\(^4\). We found phospho-Akt1 is also decreased in RPE from human DR donors and experimental diabetic mice; such reduction in Akt1 activity was independent from PI3K/PDK1 signaling but dependent on the accumulation of ceramide in the RPE. Akt1 isoforms are known to have compensatory and complementary roles in diabetes\(^6\). Here, we demonstrate that knocking out Akt2 specifically in the RPE upregulates total Akt1 in both nondiabetic and diabetic RPE, while phospho-Akt1 was only upregulated in diabetic RPE, suggesting the involvement of a signaling cascade that regulates the phosphorylation status of Akt1. In line with these observations, it has previously been reported that knockdown of Akt1 promotes Akt2 upregulation in human lens epithelial cells, suggesting a similar compensatory interplay between these two isoforms in the lens\(^7\). Conversely, mice lacking Akt2 showed stress-induced photoreceptor degeneration that was not complemented by Akt1\(^7\). Collectively, these studies demonstrate the complex relationship between Akt isoforms in different tissues in ocular disease.

The mechanism underlying the compensation between the two Akt isoforms requires further investigation. However, our studies suggest that this compensation could play a critical role for the development of early DR. The induction of diabetes increased the levels of retinal inflammatory proteins and ROS production, ultimately leading to retinal capillary degeneration and vascular leakage in both WT and Akt2\(^-/-\) mice. RPE-specific Akt2 cKO successfully inhibited these diabetes-induced retinal abnormalities, supporting a role for the RPE in the development of DR and suggesting that Akt1 signaling in the RPE may be involved in maintaining retinal homeostasis. Since inflammation plays a detrimental role in the progression of DR\(^8\), and Akt1 is known to regulate inflammation\(^9\), we propose that the protective effect observed in the RPE-specific Akt2 cKO diabetic mice could be mediated by regulation of inflammation by the compensatory increase in Akt1.

Akt1 is a multifunctional kinase that can phosphorylate multiple targets\(^10\). We have found that phospho-GSK3ß, a critical Akt1 downstream effector known to regulate inflammatory responses, including immune cell infiltration and activation\(^10\), was also increased concomitantly in the RPE. Importantly, GSK3ß is known to control activation of NF-κB, which has been described as a promising target in the management of vascular complications of diabetes, including DR\(^11\). Our data support the premise that Akt2 cKO in the RPE has a protective effect against diabetes-induced retinal damage, including infiltration and activation of immune cells, by mediating the Akt1/GSK3ß/NF-κB signaling axis. The premise is further supported by the observation that Akt2 KO showed no protective effect in the diabetic retina because the overexpression of Akt2 did not affect the level of phospho-Akt1 in the RPE. Our studies further suggest that targeting Akt1 in RPE could be an effective approach to treat DR. Herein we show that increasing Akt1 activity in retina/RPE attenuated diabetes-induced retinal molecular alterations and that reduction of Akt1 activity in RPE accelerated retinal pathological vascular damage in diabetic mice. Collectively, our results expose the complex interplay between Akt isoforms and a compensatory mechanism in Akt signaling in the RPE during the progression of DR and identify a pathway that could be manipulated to develop new therapies for the treatment of diabetic eye disease (Fig. 10).

**Methods**

**Animals**

Wild type C57BL/6j mice were purchased from The Jackson Laboratory (Stock number: 000664, Bar Harbor, ME). RPE-specific Akt2 KI mice were engineered by Cyagen (Santa Clara, CA). Briefly, the strategy is based on the insertion of the T2A sequence followed by the Akt2 coding sequence (CDS) between the last exon and the 3′ untranslated region (3′UTR) of the mouse Best1 gene. The T2A sequence enables the co-expression of both sequential genes (in this case, Best1 and Akt2) from the same Best1 promoter, which is specific to the RPE. The Neo cassette flanked with self-deletion anchors (SDA) was inserted in the intron area between exons 11 and 12 of the mouse Best1 to be deleted in germ cells. RPE-specific Akt2 K0 mice were generated by mating the Akt2\(^-/-\) mice (The Jackson Laboratory, Stock number: 026475) with Best1/Cre mice (The Jackson Laboratory, Stock number: 017557) followed by cross-mating the progeny to generate the Cre-expressing mice homozygous for the Akt2\(^-/-\). The Akt2\(^-/-\) mice possess lox\(^P\) sites flanking exons 4 and 5 of Akt2; the Best1/Cre mice express Cre recombinase under the control of the Best1 promoter. Thus, mating these two strains results in progeny, where exons 4 and 5 of Akt2 are excised by Cre recombinase controlled by the Best1 promoter, making the resulting Akt2 protein dysfunctional only in the RPE. All animals including male and female were housed in ventilated microisolator cages under a 12/12 h of light and dark cycle. The temperature and humidity are controlled. All animal studies were conducted in accordance with the guide for the care and use of animals (National Academy Press) and were approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. Protocol number is 20108281.

**Induction of diabetes**

Male mice around 2 months of age were intraperitoneally injected with streptozotocin (STZ, Sigma-Aldrich, STZ30) suspended in citrate buffer at a concentration of 60 mg/kg for five consecutive days. Nonfasting blood glucose was measured at 10am on days 7–15 after the last STZ injection. The onset of diabetes was defined as blood glucose readings exceeding 275 mg/dl on three different days. The number of months of diabetes described in the text is defined as the age of the mice at the time of sacrifice minus the age when they were first confirmed to be diabetic. To assess the severity of hyperglycemia or diabetic status, HbA1c was measured using the Mouse HbA1c Assay Kit (Crystal Chem, 80310) and its control (Crystal Chem, 80313). Body weight was monitored within 2–3 weeks after the injection of STZ. To prevent weight loss while still allowing hyperglycemia, subcutaneous injection of insulin (0–0.2 units, Inivtrogen, 12585014) was administered as needed.

**Western blotting**

RPE and retina lysates were prepared using RIPA lysis buffer\(^12\). Briefly, the mouse was euthanized by CO\(_2\) asphyxiation, the fresh isolated RPE/Choroid/Sclera complexes and retina were placed into RIPA lysis buffer from the RPE/Choroid/Sclera complexes by tapping for 30 s, Choroid/Sclera complexes were then removed by forceps. The human fetal RPE cells derived from healthy human RPE cells and are primary
Reduction in retinal capillary degeneration and vascular leakage even after an 8 month duration of diabetes. Such beneficial effects were indicative of the compensatory upregulation of Akt in the diabetic Akt2 cKO RPE cells, which downregulated GSK3β/NF-κB mediated inflammatory molecules like ICAM-1, iNOS, VEGF, TNF-α, IFN-γ and IL-1β in cKO RPE cells even after diabetes induction.

**Fig. 10 | Schematic.** RPE-specific Akt2 cKO reduced the diabetes-mediated induction of the inflammatory protein level, infiltration of leukocytes and production of ROS in the retina after a 2 month duration of diabetes. Akt2 cKO also showed reduction in retinal capillary degeneration and vascular leakage even after an 8 month duration of diabetes. Such beneficial effects were indicative of the compensatory upregulation of Akt in the diabetic Akt2 cKO RPE cells, which downregulated GSK3β/NF-κB mediated inflammatory molecules like ICAM-1, iNOS, VEGF, TNF-α, IFN-γ and IL-1β in cKO RPE cells even after diabetes induction.
secondary antibody Donkey anti-Rabbit, Alexa Fluor 488 (1:200, Invitrogen, A21206), Donkey anti-mouse, Alexa Fluor 488 (1:200, Invitrogen, A21202), Goat anti-Rabbit, Alexa Fluor 568 (1:200, Invitrogen, A10101), 1 µg/ml DAPI (1:400, Thermo Fisher, D1306), and Alexa Fluor 594 conjugated ZO-1 (1:200, Invitrogen, 339194) antibody were applied to appropriate samples for 1 h incubation at room temperature. RPE flatmounts and retinal sections were cover slipped with DAKO mounting medium (Agilent, S3023). Images were acquired by Zeiss LSM 710 confocal microscopy.

Leukostasis
The animals were anesthetized and the chest cavity was cut open to expose the heart. The mice were perfused with pre-warmed saline buffer for two min to remove free blood, followed by 10 ml of diluted concanavalin A-FITC solution (1:50, Vector Laboratories, FL-1001) for 1 min, followed by an additional 2 min of saline. Then, the eyes were enucleated, retinas were isolated and flat-mounted on a slide, and the FITC-labeled leukocytes in blood vessels of the whole retina were counted using a Zeiss LSM 710 confocal microscope (Carl Zeiss Meditec, Jena, Germany).

Superoxide and reactive oxygen species
Superoxide levels were assessed by lucigenin (bis-N-methylacridinium nitrate)42 . Freshly isolated retinas were incubated in 200 µl Krebs-Hepes buffer with 5 mM or 25 mM glucose (Sigma-Aldrich, G8644) for 5 min at 37 °C in 5% CO2. Lucigenin (Sigma-Aldrich, M8010) was added to each sample to a final concentration of 0.54 µM and incubated for 5 min. The luminescence was measured by a Glomax 20/20 luminometer (Promega, USA) and reported in arbitrary units per mg of retinal protein.

Histochemical assays for ROS and superoxide levels were conducted by staining unfixed retinal cryosections with 2′,7′-Dichloro- fluorescin diacetate (DCF, Sigma-Aldrich, D6833) and Dibydroethidium (DHE, Fisher Scientific D1347). Mouse eyes were freshly collected, embedded in OCT compound (Fisher Scientiﬁc) and frozen immediately on dry ice. Samples were cut into sections at a thickness of 12 μm and kept frozen during sectioning. Slides were immersed into ice-cold acetone for 10 min at −20 °C, warmed to room temperature for 20 min, and washed in PBS 3 times for 5 min per wash. Slides were then incubated with DCF 10 μM for 20 min, washed in PBS, and mounted on a slide, and the FITC-BSA concentration was measured using a Synergy microplate reader (Biotek), based on standard curves of FITC-BSA in normal mouse plasma with excitation at 433 nm and emission at 455 nm.

Leakage of albumin into neural retina
Diabetes was induced at 2 months of age, and the mice were sacrificed after an 8 month duration of induction. The leakage of albumin into the neural retina was measured31,32 . Sterile FITC-BSA (Sigma-Aldrich, A9771) was prepared in PBS at a concentration of 50 µg/µL, then injected into the intracardiac tail vein at 100 µg/g body weight and allowed to circulate for 20 min. Mice were then euthanized and blood samples collected and centrifuged at 2000 g for 10 min. 200 µl of 1:1000 PBS-diluted plasma was transferred into 96 well plates, and the FITC-BSA concentration was measured using a Synergy microplate reader (Biotek), based on standard curves of FITC-BSA in normal mouse plasma with excitation at 433 nm and emission at 455 nm.

Acellular capillaries
Mouse eyes were collected from diabetic (8 months of diabetes) and age-matched control (6 months of age). After overnight dark adaptation, mice were anesthetized with ketamine (87.5 mg/kg) and xylazine (12.5 mg/kg). The pupils were dilated with 0.5% tropicamide (Medline, 17478-0101-12). Two images were acquired using SD-OCT (Bioptigen, USA) and averaged, and the thickness of the retinal ONL was measured at distances of 150, 300, and 430 μm from the optic nerve. The entire retina thickness was measured at distances of 300 μm from the optic nerve.

Leakage of albumin into neural retina
Diabetes was induced at 2 months of age, and the mice were sacrificed after an 8 month duration of induction. The leakage of albumin into the neural retina was measured31,32 . Sterile FITC-BSA (Sigma-Aldrich, A9771) was prepared in PBS at a concentration of 50 µg/µL, then injected into the intracardiac tail vein at 100 µg/g body weight and allowed to circulate for 20 min. Mice were then euthanized and blood samples collected and centrifuged at 2000 g for 10 min. 200 µl of 1:1000 PBS-diluted plasma was transferred into 96 well plates, and the FITC-BSA concentration was measured using a Synergy microplate reader (Biotek), based on standard curves of FITC-BSA in normal mouse plasma with excitation at 433 nm and emission at 455 nm.

Superoxide and reactive oxygen species
Superoxide levels were assessed by lucigenin (bis-N-methylacridinium nitrate)42 . Freshly isolated retinas were incubated in 200 µl Krebs-Hepes buffer with 5 mM or 25 mM glucose (Sigma-Aldrich, G8644) for 5 min at 37 °C in 5% CO2. Lucigenin (Sigma-Aldrich, M8010) was added to each sample to a final concentration of 0.54 µM and incubated for 5 min. The luminescence was measured by a Glomax 20/20 luminometer (Promega, USA) and reported in arbitrary units per mg of retinal protein.

Histochemical assays for ROS and superoxide levels were conducted by staining unfixed retinal cryosections with 2′,7′-Dichloro-fluorescin diacetate (DCF, Sigma-Aldrich, D6833) and Dibydroethidium (DHE, Fisher Scientific D1347). Mouse eyes were freshly collected, embedded in OCT compound (Fisher Scientific, NC1029572 T), and frozen immediately on dry ice. Samples were cut into sections at a thickness of 12 μm and kept frozen during sectioning. Slides were immersed into ice-cold acetone for 10 min at −20 °C, warmed to room temperature for 20 min, and washed in PBS 3 times for 5 min per wash. Slides were then incubated with DCF 10 µM or DHE 0.625 µM for 60 min and 20 min, respectively, at room temperature in the dark. Sections were washed with PBS 3 times for 5 min, covered with coverslips using DAPI Fluoromount-G (SouthernBiotech, 0100-20) reagent, and photographed using confocal microscopy (Zeiss LSM 710). DCF green fluorescence intensity was measured at the photoreceptors’ inner and outer segments. DHE red fluorescence intensity was quantified by the nuclei of the ONL and INL layers because DHE stains DNA red in the presence of superoxide.

Acellular capillaries
Mouse eyes were collected from diabetic (8 months of diabetes) and age-matched nondiabetic mice; samples were fixed in 4% buffered paraformaldehyde (Alfa Aesar, J61899-AP) for 2 days at room temperature. Retinas were isolated and washed overnight in water and incubated in elastase (EMD Millipore, 324682) solution 40 unit/ml, followed by incubation in Tris buffer pH 8.5 over-night at room temperature. Retinal neurons were washed and brushed away from the vasculature. The carefully isolated vasculature was placed on a glass slide and dried for 24 h; samples were then stained with hematoxylin (Fisher Scientific, SH26-500D) and periodic acid Schiff reagent (Fisher Scientific, S532-500). Acellular capillaries reported per square millimeter of retinal area were identified as capillary-sized vessel tubes with no nuclei along their length. Six field areas were counted per retina corresponding to the mid-retina31.
(Diagnosys, Lowell, MA), and the retinal responses recorded by placing electrode on each cornea; the subdermal reference was placed on the nose, and ground needle electrodes were placed at the base of the tail. The full-field flash ERG responses from both eyes were recorded on mice dark-adapted overnight followed by light-adaptation (10 min of 30 cd/m² light); the flash intensities were 0.01, 0.1, 0, and 10 cd*s/m² with a 2- to 5-s interstimulus interval. The amplitude of ERG a-wave was measured from the trough of the first corneal negative deflection to the pre-stimulus baseline. The amplitude of the b-wave was calculated from the a-wave amplitude to the peak of the b-wave. The c-wave was measured in response to 2.5 cd*s/m² stimuli immediately before light adaptation. All ERG a-, b-, and c-wave amplitudes were automatically calculated by Espion V6 software (Diagnosys LLC).

**RPE explant culture**

RPE explants from 2 months diabetic mice and age-matched non-diabetic Akt2cKO and Akt2 cKO mice were flat-mounted on polyvinylidene fluoride (PVDF) transfer membranes (Thermo Fisher, 22860) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) medium (Thermo Fisher, 12320032) in 24-well plates for 48 h. RPE flatmounts from non-diabetic mice were cultured in DMEM medium containing 5.5 mM D-glucose (Sigma Aldrich, G8644), 2% FBS (Thermo Fisher, 10082147), while RPE flatmounts isolated from diabetic mice were cultured in the medium containing 5 mM D-glucose and 2% FBS. NAC (500 μM; dissolved in DMSO), and LY294002 (10 μM; dissolved in DMSO) were used in RPE explant treatment, in this case RPE flatmounts were cultured in medium containing 0.05% DMSO (vehicle control).

**ELISA**

The Multi-Analyte ELISArray Kit (33616, QIAGEN) was used to measure the levels of mouse retinal inflammatory cytokines. The RPE with retina tissue was isolated from Akt2cKO and Akt2 cKO diabetic (2 months of diabetes) and non-diabetic control mice. Tissue was homogenized in 300 μl of complete extraction buffer (Abcam, ab193970). The supernatant was collected from the lysate by centrifuging it at 10 000 x g for 10 min at 4 °C. The detailed procedure followed the manufacturer’s instructions. The absorbance was measured at 450 nm using a microplate reader. RPE-choroid was isolated from the same groups in the RPE at-mount culture experiment as described above. The RPE flatmounts were cultured in DMEM (Thermo Fisher Scientific, 12320032) with 2% FBS for 48 h. The culture medium with 5 mM D-glucose was used for non-diabetic RPE, and 25 mM D-glucose was used for diabetic mouse RPE flat-mount culture. An Akt1 inhibitor (Selleck Chemicals, S2670) was dissolved in DMSO at a stock concentration of 10 mM, and Akt2 cKO diabetic RPE flatmounts were treated with the Akt1 inhibitor at a final concentration of 40 nM for 48 h. The flatmount culture medium was then collected, and the same Multi-Analyte ELISArray Kit mentioned above was used to measure the inflammatory cytokines, while RPE flatmount tissue was lysed for western blot analysis.

**Flow cytometry**

For quantification of immune cells in the mouse RPE and retina, mouse retina and RPE-choroid were gently dissected and digested with 1.5 mg/ml collagenase A (Sigma-Aldrich, 10103578010) and 0.4 mg/ml DNase 1 (Sigma-Aldrich, 11284932001) at 37 °C for 1 h. Single-cell suspensions were generated by pipetting the tissue to release cells and passing cells through 70 μm filters. Cells were blocked with 1% mouse serum (Thermo Fisher Scientific, 10410) and 1 μg/μl Fc blocker (BD Biosciences, 553142), followed by antibody staining including BV650 Rat Anti-Mouse CD11b, (BD Biosciences, 563402, MI/70), PE-Cy7 Rat anti-Mouse CD45 (BD Biosciences, 561868), FITC Rat anti-Mouse CCR2 (SC203G11) (BioLegend, 150607), APC Rat Anti-Mouse Ly-6G (BD Biosciences, 560399, IAB) and BV421 Rat Anti-Mouse Ly-6C (BD Biosciences, 562727, AF-21) in brilliant stain buffer (BD Biosciences, 563794,) at a concentration of 1 μg/mL for 30 min at room temperature. Flow cytometry was used to estimate the number of immune cells in the RPE/retina.

**siRNA transfection**

The signal silence control siRNA (6568, Cell Signaling Technology) and Akt2 siRNA (6396, Cell Signaling Technology) were commercially obtained. The siRNAs were transfected into RPE cells using Lipofectamine 3000 (L3000008, Thermo Fisher Scientific) following the manufacturer’s protocol. The silencing efficiency was detected by western blotting 48 h after transfection.

**Immunocytochemistry**

The human fetal RPE cells derived from healthy human RPE cells, and were a gift from Dr. Ram Kannan. Informed consent was obtained for their use. Human RPE cells were not seeded on cell culture cover glasses (Fisher Scientific, NCO620709) in a 24-well plate. On the second day, ASM inhibitor desipramine hydrochloride (2 μM, D3900, Sigma-Aldrich) was added and the cells were cultured in 5 mM, 25 mM D-glucose, and 25 mM mannitol medium for four additional days. Then, each well was washed with PBS followed by 2% PFA for 15 min at room temperature. The cells were then permeabilized with 0.1% Triton X-100 in PBS for 20 min, followed by 2% BSA, 2% donkey serum, and 0.05% Triton X-100 in PBS for 1 h at room temperature. Next, the samples were incubated at 4 °C overnight with an anti-ceramide antibody, (Sigma, C8140, 15B4) at a 1:200 dilution. After three washes with PBS, the cells were incubated with AF-488 conjugated donkey anti-mouse secondary antibody at a 1:200 dilution and DAPI at a 1:600 dilution for 1 h at room temperature. Following incubation, the cover slides were removed from the 24-well plate, and the antifade medium was applied. The cells were then washed six times with PBS and placed on a slide. Finally, five images were acquired by Zeiss LSM 710 confocal microscopy at different fields of view for each sample to quantify the fluorescence intensity. The average fluorescence intensity of each cell was normalized to a control group where human RPE were grown in a 5 mM glucose medium. The experiments were repeated four times.

**Quantitative real-time polymerase chain reaction**

According to the manufacturer’s instructions, total RNA was extracted from human RPE cells grown in 5 mM, 25 mM D-glucose, and 25 mM mannitol medium using an Isolate II RNA Mini Kit (BIO-52072, Bioline), and cDNA was generated using a SuperScript® VILO™ cDNA Synthesis Kit (11754-050, Invitrogen). Human ASM: Fwd: 5′-CAA CTC GGG CCT GAA GAA-3′; Human ASM: Rev: 5′-TCC ACC AGT TCA TCG TCA AAA-3′; Human Cyclophilin: Fwd: 5′-CAA GAC TAG GTG GAT GTA TGG-3′; Human Cyclophilin: Rev: 5′-TGG TGA TCT TCT TCG TCT TGC TCT-3′ ordered from Integrated DNA Technologies were mixed with Applied Biosystems SYBR Green Master Mix (A25742, Thermo Fisher Scientific). The mRNA expression of each target was evaluated using a QuantStudio 3 qPCR machine (A28131, Applied Biosystems by Thermo Fisher Scientific). Then, the gene expression levels were normalized relative to Cyclophilin mRNA and reported as fold change over controls using the Delta-Delta Ct method.

**Statistical analysis**

Statistical analysis was performed using GraphPad 9.0 software (GraphPad Software, Inc., La Jolla, CA, USA) and Excel (Microsoft, version 16.34). All data were expressed as mean ± SD. Two-tailed, unpaired t-test was used to evaluate the mouse retina/RPE expression of inflammatory cytokines. To evaluate the significant differences for the rest of the data, One-way ANOVA followed by Tukey’s post hoc test was used for multiple-group comparisons.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
This study includes no data deposited in external repositories. All data generated or analyzed during this study are included in the article and its Supplementary Information files. Generation and validation of RPE-specific Akt2 cKO and Akt2 KI mice. OCT, data for gain and loss of function of Akt1 in the RPE, clinical data of nondiabetic and diabetic mice, human data and basic characteristics of human RPE cadaver tissue donors are provided in the Supplementary Information files. Source data are provided with this paper.

References
1. Wong, T. Y., Cheung, C. M., Larsen, M., Sharma, S. & Simo, R. Diabetic retinopathy. Nat. Rev. Dis. Prim. 2, 16012 (2016).
2. Resnikoff, S. et al. Global data on visual impairment in the year 2002. Bull. World Health Organ 82, 844–851 (2004).
3. Semeraro, F. et al. Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. Diabetes Metab. 45, 517–527 (2019).
4. Fong, D. S., Aiello, L. P., Ferris, F. L. 3rd & Klein, R. Diabetic retinopathy. Diabetologia 27, 2540–2553 (2004).
5. Wang, W. & Lo, A. C. Y. Diabetic retinopathy: pathophysiology and treatments. Int. J. Mol. Sci. 19, 1816 (2018).
6. Ciulla, T. A., Amador, A. G. & Zinman, B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26, 2653–2664 (2003).
7. Cheung, N., Mitchell, P. & Wong, T. Y. Diabetic retinopathy. Lancet 376, 124–136 (2010).
8. Duh, E. J., Sun, J. K. & Stitt, A. W. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2, e93751 (2017).
9. Martin, P. M., Roon, P., Van Ellis, T. K., Ganapathy, V. & Smith, S. B. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest. Ophthalmol. Vis. Sci. 45, 3330–3336 (2004).
10. Coughlin, B. A., Feenstra, D. J. & Mohr, S. Muller cells and diabetic retinopathy. Vis. Res. 139, 93–100 (2017).
11. Ghosh, S. et al. betaA1-crystallin regulates glucose metabolism and mitochondrial function in mouse retinal astrocytes by modulating PTP1B activity. Commun. Biol. 4, 248 (2021).
12. Rungger-Brandl, E., Dosso, A. A. & Leuenberger, P. M. Glial activity, an early feature of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 41, 1971–1980 (2000).
13. Omri, S. et al. Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCzeta in the Goto Kakizaki rat model. Am. J. Pathol. 179, 942–953 (2011).
14. Gastlinger, M. J., Kunselman, A. R., Conboy, E. E., Bronson, S. K. & Barber, A. J. Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest. Ophthalmol. Vis. Sci. 49, 2635–2642 (2008).
15. Gastlinger, M. J., Singh, R. S. & Barber, A. J. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest. Ophthalmol. Vis. Sci. 47, 3143–3150 (2006).
16. Tonade, D., Liu, H. & Kern, T. S. Photoreceptor cells produce inflammatory mediators that contribute to endothelial cell death in diabetes. Investig. Ophthalmol. Vis. Sci. 57, 4264–4271 (2016).
17. Tonade, D., Liu, H., Palczewski, K. & Kern, T. S. Photoreceptor cells produce inflammatory products that contribute to retinal vascular permeability in a mouse model of diabetes. Diabetologia 60, 2111–2120 (2017).
18. Pierce, E. A., Avery, R. L., Foley, E. D., Aiello, L. P. & Smith, L. E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl Acad. Sci. USA 92, 905–909 (1995).
43. Zafar, S., Sachdeva, M., Frankfort, B. J. & Channa, R. Retinal neurodegeneration as an early manifestation of diabetic eye disease and potential neuroprotective therapies. Curr. Diab Rep. 19, 17 (2019).

44. Peltman, I. The Electrorretinogram: ERG. In: Webvision: The Organization of the Retina and Visual System (eds Kolb B, Fernandez E, Nelson R) (University of Utah Health Sciences Center, 1995).

45. Fu, Z. et al. Fibroblast growth factor 21 protects photoreceptor function in Type 1 diabetic mice. Diabetes 67, 974–985 (2018).

46. Applebury, M. L. et al. The murine cone photoreceptor: a single cone type expresses both S and M opsins with retinal spatial patterning. Neuron 27, 513–523 (2000).

47. Patel, N. Targeting leukostasis for the treatment of early diabetic retinopathy. Cardiovasc. Hematol. Disord. Drug Targets 9, 222–229 (2009).

48. Li, C. et al. Oxidative stress-related mechanisms and antioxidants therapy in diabetic retinopathy. Oxid. Med. Cell Longev. 2017, 9702820 (2017).

49. Rubsam, A., Parikh, S. & Fort, P. E. Role of inflammation in diabetic retinopathy. Int. J. Mol. Sci. 19, (2018).

50. Ghosh, S. et al. Activating the AKT2-nuclear factor-kappaB-lipocinal-2 axis elicits an inflammatory response in age-related macular degeneration. J. Pathol. 241, 583–588 (2017).

51. Tarr, J. M., Kaul, K., Chopra, M., Kohner, E. M. & Chibber, R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013, 343560 (2013).

52. Li, G. et al. Marrow-derived cells regulate the development of early diabetic retinopathy and tactile allodynia in mice. Diabetes 61, 3294–3303 (2012).

53. Berkowitz, B. A., Gradianu, M., Bissig, D., Kern, T. S. & Roberts, R. Retinal ion regulation in a mouse model of diabetic retinopathy: natural history and the effect of Cu/Zn superoxide dismutase overexpression. Investig. Ophthalmol. Vis. Sci. 50, 2351–2358 (2009).

54. Kowluru, R. A., Tang, J. & Kern, T. S. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 50, 1938–1942 (2001).

55. Semeraro, F. et al. Diabetic retinopathy: vascular and inflammatory disease. J. Diabetes Res. 2015, 582065 (2015).

56. Liu, H. et al. Transducin1, phototransduction and the development of early diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 60, 1538–1546 (2019).

57. Tian, P. et al. Leukocytes from diabetic patients kill retinal endothelial cells: effects of berberine. Mol. Vis. 19, 2092–2105 (2013).

58. Joussen, A. M. et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18, 1450–1452 (2004).

59. Veenstra, A. A., Tang, J. & Kern, T. S. Antagonism of CD11b with neutrophil inhibitory factor (NIF) inhibits vascular lesions in diabetic retinopathy. PLoS ONE 8, e78405 (2013).

60. Liu, H. et al. Neutrophil elastase contributes to the pathological vascular permeability characteristic of diabetic retinopathy. Diabetologia 62, 2365–2374 (2019).

61. Hoffmeister, L., Diekmann, M., Brand, K. & Huber, R. GS K3: a kinase balancing promotion and resolution of inflammation. Cells 9, 820 (2020).

62. Hao, Y., Liu, J., Wang, Z., Yu, L. L. & Wang, J. Piceatannol Protects Human Retinal Pigment Epithelial Cells against Hydrogen Peroxide Induced Oxidative Stress and Apoptosis through Modulating PI3K/ Akt Signaling Pathway. Nutrients 11, 1515 (2019).

63. Levitsky, Y. et al. Mitochondrial Ceramide Effects on the Retinal Pigment Epithelium in Diabetes. Int. J. Mol. Sci. 21, 3830 (2020).

64. Busik, J. V. Lipid metabolism dysregulation in diabetic retinopathy. J. Lipid Res. 62, 100107 (2021).

65. Salinas, M., Lopez-Valdalsiso, R., Martin, D., Alvarez, A. & Cuadrado, A. Inhibition of PKB/Akt by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol. Cell. Neurosci. 15, 156–169 (2000).

66. Opreanu, M. et al. The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models. Diabetes 60, 2370–2378 (2011).

67. Lee, R., Wong, T. Y. & Sabanayagam, C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2, 17 (2015).

68. Testa, R. et al. The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients 9, 437 (2017).

69. Engerman, R., Bloodworth, J. M. Jr. & Nelson, S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 26, 760–769 (1977).

70. Engerman, R. L. & Kern, T. S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36, 808–812 (1987).

71. Al-Kharashi, A. S. Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy. Saud J. Ophthalmol. 32, 318–323 (2018).

72. Zheng, L., Howell, S. J., Hatala, D. A., Huang, K. & Kern, T. S. Saliyulate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56, 337–345 (2007).

73. Kern, T. S. & Engerman, R. L. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 50, 1636–1642 (2001).

74. Lorenzi, M. The polyl pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp. Diabetes Res. 2007, 61038 (2007).

75. Kondo, T. & Kahn, C. R. Altered insulin signaling in diabetic states. J. Biol. Chem. 279, 37997–38006 (2004).

76. Chen, W. S. et al. Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice. Mol. Cell Biol. 29, 3151–3162 (2009).

77. Tang, J. & Kern, T. S. Inflammation in diabetic retinopathy. Prog. Retin Eye Res. 30, 343–358 (2011).

78. Bhaskar, P. T. & Hay, N. The two TORCs and Akt. Dev. Cell 12, 487–502 (2007).

79. Suryavanshi, S. V. & Kulkarni, Y. A. NF-kappabeta: a potential target in the management of vascular complications of diabetes. Front. Pharm. 8, 798 (2017).

80. Shang, P. et al. A novel method of mouse RPE explant culture and effective introduction of transgenes using adenoviral transduction for in vitro studies in AMD. Int. J. Mol. Sci. 22, 11979 (2021).

81. Liu, H., Tang, J., Lee, C. A. & Kern, T. S. Metanx and early stages of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 56, 647–653 (2015).

82. Antonetti, D. A. et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 47, 1953–1959 (1998).

83. Lin, C. M. et al. Inhibition of atypical protein kinase C reduces inflammation-induced retinal vascular permeability. Am. J. Pathol. 188, 2392–2405 (2018).

Acknowledgements

This work was supported by University of Pittsburgh start-up funds (DS), the Jennifer Salvitti Davis, MD, Chair Professorship in Ophthalmology (DS), and Research to Prevent Blindness-NY (Ophthalmology, UPMC). The human RPE cells were a gift from Dr. Ram Kannan. Human donor cadaver eye tissues are from Lions Gift of Sight, Minnesota, and gifts from Dr. Patrice Fort.
Author contributions
D.S. designed the study and supervised the work. H.L., N.A.S., S.G., P.S., M.Y., S.L.H., R.A.D., and C.S.F., conducted the experiments and/or analyzed the data. H.L., N.A.S., S.G., N.S., J.S.Z., A. Sodhi and D.S. wrote the paper. U.G., O.C., A. Strizhakova, M.V., D.F., P.S., J.A.S., A.J., Y.S., P.E.F., and J.T.H. reviewed the data and revised the paper.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-33773-0.

Correspondence and requests for materials should be addressed to Debasish Sinha.

Peer review information Nature Communications thanks Silvia Finne-mann and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022